Holly Geyer1, Ruben A Mesa2. 1. Division of Hospital Internal Medicine, Mayo Clinic, Scottsdale, AZ, USA. 2. Division of Hematology and Medical Oncology, Mayo Clinic, 5777 E Mayo Blvd, Phoenix, AZ, 85054, USA. mesa.ruben@mayo.edu.
Abstract
PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. RECENT FINDINGS: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.
PURPOSE OF REVIEW: Myeloproliferative neoplasms (MPNs) are recognized for their debilitating symptom burdens. The purpose of this review is to understand the complexity of the MPN symptom burden and identify how validated MPN Patient Reported Outcome (PRO) tools may be integrated into clinical practice to assess the MPN symptom burden. RECENT FINDINGS: Significant heterogeneity exists both within and between MPN subtypes. Surrogates of disease burden such as risk scores and MPN chronicity often fail to correlate with symptomatic burden. Validated MPN PROs allow for precise and rapid assessment of the MPN symptom burden in clinical and trial settings. Their growing use among investigators has resulted in improved understanding of how the MPN disease burden and overall patient experience is impacted by novel and traditional therapies. PRO tools are an integral part of National Comprehensive Cancer Center (NCCN) guidelines for MPN treatment and should be regularly employed in disease burden assessment.
Authors: Srdan Verstovsek; Ruben A Mesa; Jason Gotlib; Richard S Levy; Vikas Gupta; John F DiPersio; John V Catalano; Michael Deininger; Carole Miller; Richard T Silver; Moshe Talpaz; Elliott F Winton; Jimmie H Harvey; Murat O Arcasoy; Elizabeth Hexner; Roger M Lyons; Ronald Paquette; Azra Raza; Kris Vaddi; Susan Erickson-Viitanen; Iphigenia L Koumenis; William Sun; Victor Sandor; Hagop M Kantarjian Journal: N Engl J Med Date: 2012-03-01 Impact factor: 91.245
Authors: Alexandra P Wolanskyj; Terra L Lasho; Susan M Schwager; Rebecca F McClure; Martha Wadleigh; Stephanie J Lee; D Gary Gilliland; Ayalew Tefferi Journal: Br J Haematol Date: 2005-10 Impact factor: 6.998
Authors: Thorsten Klampfl; Heinz Gisslinger; Ashot S Harutyunyan; Harini Nivarthi; Elisa Rumi; Jelena D Milosevic; Nicole C C Them; Tiina Berg; Bettina Gisslinger; Daniela Pietra; Doris Chen; Gregory I Vladimer; Klaudia Bagienski; Chiara Milanesi; Ilaria Carola Casetti; Emanuela Sant'Antonio; Virginia Ferretti; Chiara Elena; Fiorella Schischlik; Ciara Cleary; Melanie Six; Martin Schalling; Andreas Schönegger; Christoph Bock; Luca Malcovati; Cristiana Pascutto; Giulio Superti-Furga; Mario Cazzola; Robert Kralovics Journal: N Engl J Med Date: 2013-12-10 Impact factor: 91.245
Authors: Holly L Geyer; Heidi Kosiorek; Amylou C Dueck; Robyn Scherber; Stefanie Slot; Sonja Zweegman; Peter Aw Te Boekhorst; Zhenya Senyak; Harry C Schouten; Federico Sackmann; Ana Kerguelen Fuentes; Dolores Hernández-Maraver; Heike L Pahl; Martin Griesshammer; Frank Stegelmann; Konstanze Döhner; Thomas Lehmann; Karin Bonatz; Andreas Reiter; Francoise Boyer; Gabriel Etienne; Jean-Christophe Ianotto; Dana Ranta; Lydia Roy; Jean-Yves Cahn; Claire N Harrison; Deepti Radia; Pablo Muxi; Norman Maldonado; Carlos Besses; Francisco Cervantes; Peter L Johansson; Tiziano Barbui; Giovanni Barosi; Alessandro M Vannucchi; Chiara Paoli; Francesco Passamonti; Bjorn Andreasson; Maria L Ferrari; Alessandro Rambaldi; Jan Samuelsson; Keith Cannon; Gunnar Birgegard; Zhijian Xiao; Zefeng Xu; Yue Zhang; Xiujuan Sun; Junqing Xu; Jean-Jacques Kiladjian; Peihong Zhang; Robert Peter Gale; Ruben A Mesa Journal: Haematologica Date: 2016-08-18 Impact factor: 9.941
Authors: Ruben A Mesa; Susan Schwager; Deepti Radia; Andrea Cheville; Kebede Hussein; Joyce Niblack; Animesh D Pardanani; David P Steensma; Mark R Litzow; Candido E Rivera; John Camoriano; Srdan Verstovsek; Jeffrey Sloan; Claire Harrison; Hagop Kantarjian; Ayalew Tefferi Journal: Leuk Res Date: 2009-02-27 Impact factor: 3.156
Authors: Holly L Geyer; Bjorn Andreasson; Heidi E Kosiorek; Amylou C Dueck; Robyn M Scherber; Kari A Martin; Kristina A Butler; Claire N Harrison; Deepti H Radia; Francisco Cervantes; Jean-Jacques Kiladjian; Andreas Reiter; Gunnar Birgegard; Francesco Passamonti; Zhenya Senyak; Alessandro M Vannucchi; Chiara Paoli; Zhijian Xiao; Jan Samuelsson; Ruben A Mesa Journal: Cancer Date: 2016-04-12 Impact factor: 6.860
Authors: J Nangalia; C E Massie; E J Baxter; F L Nice; G Gundem; D C Wedge; E Avezov; J Li; K Kollmann; D G Kent; A Aziz; A L Godfrey; J Hinton; I Martincorena; P Van Loo; A V Jones; P Guglielmelli; P Tarpey; H P Harding; J D Fitzpatrick; C T Goudie; C A Ortmann; S J Loughran; K Raine; D R Jones; A P Butler; J W Teague; S O'Meara; S McLaren; M Bianchi; Y Silber; D Dimitropoulou; D Bloxham; L Mudie; M Maddison; B Robinson; C Keohane; C Maclean; K Hill; K Orchard; S Tauro; M-Q Du; M Greaves; D Bowen; B J P Huntly; C N Harrison; N C P Cross; D Ron; A M Vannucchi; E Papaemmanuil; P J Campbell; A R Green Journal: N Engl J Med Date: 2013-12-10 Impact factor: 91.245
Authors: A Tefferi; E Rumi; G Finazzi; H Gisslinger; A M Vannucchi; F Rodeghiero; M L Randi; R Vaidya; M Cazzola; A Rambaldi; B Gisslinger; L Pieri; M Ruggeri; I Bertozzi; N H Sulai; I Casetti; A Carobbio; G Jeryczynski; D R Larson; L Müllauer; A Pardanani; J Thiele; F Passamonti; T Barbui Journal: Leukemia Date: 2013-06-06 Impact factor: 11.528
Authors: Sarah F Christensen; Robyn M Scherber; Gina L Mazza; Amylou C Dueck; Nana Brochmann; Christen L Andersen; Hans C Hasselbalch; Ruben A Mesa; Holly L Geyer Journal: BMC Cancer Date: 2021-06-10 Impact factor: 4.430
Authors: M Bao; D Y Shi; H X Shi; X L Liu; M H Duan; J L Zhuang; X Du; L Qin; W H Hui; R Liang; M F Wang; Y Chen; D Y Li; W Yang; G S Tang; W H Zhang; X Kuang; W Su; Y Q Han; L M Chen; J H Xu; Z G Liu; J Huang; C T Zhao; H Y Tong; J D Hu; C Y Chen; X Q Chen; Z J Xiao; Q Jiang Journal: Zhonghua Xue Ye Xue Za Zhi Date: 2021-12-14